By Skyepharma Production…
To get in touch with Skyepharma Production S.A.S., simply fill out the form below.
Subscribe to Supplier
Skyepharma to go its own way with MBO
Saint-Quentin-Fallavier, France: – Oral dosage specialist CDMO Skyepharma Production S.A.S. (Skyepharma) has announced a Management Buy Out (MBO) from its current owners, the Vectura Group.
Since 2016, the Skyepharma management team, led by General Manager David Lescuyer, has transformed the company into a center of excellence in formulation and manufacturing of (oral solid dose (OSD) pharmaceuticals, establishing long-term relationships with its clients built on mutual trust. The French-based CDMO has now decided it is time to continue its growth as an independent company.
Poised for further growth
Led by the current leadership team in place, this MBO is backed by the French sovereign fund BPI France and three leading French banks.
The new Skyepharma commercial entity will thus have strong financial support, and will operate as a continuation of the strategy initiated five years ago, which has demonstrated strong growth, with doubled revenue and a three-fold growth in customer base.
Skyepharma will continue investing in skilled people and state-of-the art equipment on its FDA-approved site, in order to keep delivering its international clients with best-in-class service and quality levels.
Expert OSD focus
Significantly, over the same period, Skyepharma has established world-recognized expertise and capabilities in complex solid dosage forms.
In the process, Skyepharma has also created new organizational structures and culture as part of its reinvention as a fully integrated agile and expert CDMO with specialist expertise in complex oral solid dosage (OSD) forms.
Supported by its proprietary drug delivery technologies and a strong scientific team, it is now able to offer a complete portfolio of services, including early stage development, life cycle management reformulation and commercial manufacturing and packaging.
“The winning organizational culture implemented on our site since 2016 has made Skyepharma a great place to work, with ability for all employees to perform at their best level, and be listened at, empowered, and trusted,” declared David Lescuyer.
“This project is a shared and team vision, embraced by our entire 150-expert workforce, all along with all our partners,” he continued.
“We have proven our ability to change and grow and are now set up for even stronger future growth, based on creating innovation, value and security for our clients” Mr. Lescuyer concluded.
About Skyepharma Production
Skyepharma Production S.A.S. (Skyepharma) is an oral dosage forms specialist CDMO with particular expertise and capabilities in formulating and manufacturing complex and controlled release drugs.
As an integrated CDMO, The company’s vision is to help solve healthcare industry complexity with a mission to provide a dedicated and results-oriented team to deliver advanced oral dosage services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships. All of this is summed up in its strapline: ‘Expert and Agile CDMO partner for tailor-made solutions’.
The Skyepharma CDMO offer in solid oral dosage formats encompasses the whole value chain, including Formulation Development & Process Design, Analytical Development, Scale-up, Manufacturing, Packaging, Serialization and Aggregation.
Skyepharma also provides a range of support services that help client companies from early stage development (up to phase III), through scale-up and full commercial manufacturing and packaging to market introduction, including controlled substance handling, QbD methodology (FMEA, FTA, DOE), Troubleshooting, regulatory services, validation, registration and warehousing services.
Learn more at: www.skyepharma.fr